ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - metoprolol succinate 23.75mg; metoprolol succinate 23.75mg; metoprolol succinate 23.75mg - modified release tablet - 23.75 mg - active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white 752 active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 - aft - metoprolol is indicated for the following indications: · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis.

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - felodipine; ramipril - prolonged-release tablet - 5 mg/5 milligram(s) - ace inhibitors and calcium channel blockers; ramipril and felodipine

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - felodipine; ramipril - prolonged-release tablet - 2.5 mg/2.5 milligram(s) - ace inhibitors and calcium channel blockers; ramipril and felodipine

シンガポール - 英語 - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - pneumococcal polysaccharides 23 most prevalent types - injection - 25mcg/0.5ml each - pneumococcal polysaccharides 23 most prevalent types 25mcg/0.5ml each

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; macrogol 400; ethylcellulose; sodium stearylfumarate; macrogol 6000; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; triacetin - stable, chronic heart failure as an adjunct to other heart failure therapy.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

iroko pharmaceuticals, llc - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam 5 mg - vivlodex is indicated for management of osteoarthritis pain. vivlodex is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product [see warnings and precautions (5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8) ] - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1) ] risk summary use of nsaids, including vivlodex, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including vivlodex, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of vivlodex in pregnant women. data from observational studies rega

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: titanium dioxide; glycerol; magnesium stearate; microcrystalline cellulose; stearic acid; ethylcellulose; maize starch; hypromellose; methylcellulose - stable, chronic heart failure as an adjunct to other heart failure therapy.

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

reckitt benckiser healthcare (uk) ltd - ibuprofen lysine - oral tablet - 684mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

reckitt benckiser healthcare (uk) ltd - phenylephrine hydrochloride; ibuprofen - oral tablet - 5mg ; 200mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

haleon uk ltd - diclofenac diethylammonium - cutaneous gel - 23.2mg/1gram